Qlaris Bio Announces Development of QLS-111-FDC

Qlaris Bio announces development of QLS-111-FDC

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance clinical and patient care.

Qlaris Bio Developing Fixed-Dose Combination Therapy for the Treatment of Glaucoma

Qlaris Bio announced it is developing a novel preservative-free, fixed-dose combination therapy that combines the company’s lead program, QLS-111, and latanoprost. The fixed-dose combination (QLS-111-FDC) is being developed as a treatment for patients with primary open angle glaucoma (POAG), ocular hypertension (OHT), and normal tension glaucoma (NTG) for whom optimal IOP control may remain unachievable due to the need to lower episcleral venous…